Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

The Global Market for Parkinson’s Disease Drugs to 2024 - COMT (Catechol-O-Methyltransferase) Inhibitors to Register Robust Growth - ResearchAndMarkets.com

May 10, 2019

DUBLIN--(BUSINESS WIRE)--May 10, 2019--The “Parkinson’s Disease Drugs Market - Growth, Trends, and Forecast (2019-2024)” report has been added to ResearchAndMarkets.com’s offering.

Parkinson’s disease drugs market is expected to witness significant growth, owing to the increasing cases of Parkinson’s disease, with the growth in aging population levels. Therefore, it may drastically result in increasing the market size during the forecast period.

Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease (PD), and recently, there have been some major product launches in Parkinson disease therapeutics and other assistive therapeutics.

For instance, Adamas Pharmaceuticals’ amantadine extended-release capsules / Gocovri launched in Jan 2018, which was the first drug indicated for dyskinesia developed due to long-term use of levodopa.

Furthermore, most of the global firms have a robust drug pipeline for the treatment of Parkinson’s disease, and as per the estimates, the forecast period may witness the launch of a few blockbuster drugs.

Key Market Trends

COMT (Catechol-O-Methyltransferase) Inhibitors are Expected to Register Robust Growth

Carbidopa-levodopa Therapy is the most effective medication for alleviating the motor symptoms of PD. However, it has been observed that this medication is not as effective as intended. Therefore, it is imperative that co-therapeutic agents, such as COMT (catechol-O-methyltransferase) inhibitors, are used along with carbidopa-levodopa therapy.

The two most common COMT inhibitors, used in the treatment of Parkinson’s disease, are Comtan (entacapone) and Tasmar (tolcapone). Both these medications are available in the form of tablets. In addition, these medications are routinely prescribed in conjunction with carbidopa-levodopa therapy.

The United States Represents the Largest Market for Parkinson’s Disease Therapeutics

According to the National Institute of Health, approximately 1.2 million people in the United States are predicted to have Parkinson’s disease by 2030. It is the second-most common neurodegenerative disorder in the United States. In addition, there are thousands of patients who go undetected. As the aging population levels continue to grow, the number of people suffering from Parkinson’s disease (PD) will continue to grow, and this is expected to double by 2040.

The sheer number of Parkinson’s disease patients, combined with the availability of reimbursements and high awareness, is boosting the growth of the market. Furthermore, the high cost of Parkinson’s disease therapeutics in the United States also leads to significant market size in terms of revenue. The average cost of Parkinson’s medication is approximately USD 2,500 per year and Parkinson’s-related surgery can cost up to USD 100,000 per patient.

Competitive Landscape

Parkinson’s disease drugs market is becoming highly competitive. The recent product launches and the high number of therapeutics in product pipelines of global pharmaceutical firms are contributing to the dynamic nature of the market. Several new product launches are expected during the forecast period, which may lead to significant changes in market shares of pharmaceutical firms currently active in the market.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Geriatric Population

4.2.2 Recent Drug Approvals

4.2.3 Growing Awareness

4.3 Market Restraints

4.3.1 Generic Competition to Key Therapies

4.3.2 High Cost of Treatment

4.4 Porter’s Five Forces Analysis


5.1 By Mechanism of Action

5.1.1 Dopamine Agonists

5.1.2 Anticholinergic

5.1.3 MAO-B inhibitors

5.1.4 Amantadine

5.1.5 Carbidopa-levodopa

5.1.6 COMT Inhibitors

5.1.7 Other Mechanisms of Action

5.2 Geography

5.2.1 North America

5.2.2 Europe

5.2.3 Asia-Pacific

5.2.4 Middle East & Africa

5.2.5 South America


6.1 Company Profiles

6.1.1 Merck & Co. Inc.

6.1.2 Impax Laboratories Inc.

6.1.3 AbbVie Inc.

6.1.4 Mylan N.V.

6.1.5 Boehringer Ingelheim

6.1.6 GlaxoSmithKline plc

6.1.7 M Somerset Pharmaceuticals Inc.

6.1.8 Teva Pharmaceuticals Industries Ltd.

6.1.9 Pfizer Inc.

6.1.10 Novartis AG


For more information about this report visit https://www.researchandmarkets.com/r/db4upx

View source version on businesswire.com:https://www.businesswire.com/news/home/20190510005183/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/10/2019 06:28 AM/DISC: 05/10/2019 06:28 AM


All contents © copyright 2019 The Associated Press.All rights reserved.